We compared the structure and content of guidelines for hypertension management across countries to gain an understanding of where differences between them originate from. Four guidelines published between 2003 and 2006 were selected. Two were issued by national agencies in the United Kingdom and France, and two were issued by working groups or national medical societies in the United States and in Europe. The structure of guidelines, the content of each section and their underlying bibliographic references were compared between authoring bodies. If differences were found between guidelines in terms of content, we analysed the rationales. The guidelines were sufficiently similar in structure, showing common sections such as lifestyle interventions, cardiovascular risk assessment and drug therapies. However, contentwise, major differences were observed across the four hypertension guidelines in virtually every section of the document.
Introduction
The exponential increase in available medical information with time, 1 variability in medical practices 2, 3 and persistent levels of inappropriate care 4, 5 are the main reasons for the development of clinical guidelines since the 1970s. These guidelines, an application of evidence-based medicine, have been developed by a number of national agencies, including the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom, the Scottish Intercollegiate Guidelines Network (SIGN) in Scotland, the National Authority for Health (HAS) in France, working groups or national medical societies, such as the Joint National Committee for hypertension (JNC-7) in the United States, and the European Society of Cardiology (ESC) and European Society of Hypertension (ESH). These agencies and scientific groups have tended to develop clinical guidelines on similar topics at the same time.
Clinical guidelines may differ in terms of their content and recommendations, 6 which can be confusing to physicians. 7 McAlister et al. 8 recently compared the evidence underlying therapy recommendations for nine clinical guidelines relating to chronic diseases and found that less than one-third of treatment recommendations were based on highquality evidence. Variations in the content of recommendations may limit their implementation and their applicability by physicians. The use of different guidelines for hypertension management 9, 10 results in very different number of patients receiving treatment, very different benefits 11 and significant variations in practice. 12 Two types of guideline assessment methods are currently used. The first one is based on the assessment of the guideline as a whole using the Appraisal of Guidelines Research and Evaluation (AGREE) checklist. 13, 14 However, this approach does not make it possible to focus on the specific recommendations that physicians should apply in practice. The second approach is based on the applicability of guidelines to real patients, and compares recommended treatments. 15 This study explored the consistency of several hypertension guidelines, by assessing the documents' structure and contents, leaving aside any issues deriving from their potential interpretation by the physicians. Substantial differences were observed in the content of four guidelines issued over a 3-year period.
Methods

Selection of clinical guidelines
We performed a detailed comparison of four guidelines, published between 2003 and 2006, among a dozen published internationally. We selected these guidelines to constitute a homogeneous sample in terms of publication date and focus (hypertension management rather than cardiovascular risk). These guidelines are also similar in terms of objective, structure and content. Our underlying hypothesis was that differences encountered within such a homogeneous sample would be more significant and could not be accounted for by differences in focus or evolution of the discipline. Two of these guidelines were issued by national agencies, All these guidelines were developed in similar manner, beginning with the selection of scientific literature from standard databases, followed by the writing up of guidelines by a specific committee and the review of these guidelines by external experts. Two types of documents were published: the clinical guidelines themselves and the underlying rationales (published as a separate document). The rationales describe the analysis of background literature and how it informed the discussions within the working group. They thus contain all bibliographic references, the interpretation and the synthesis of the evidence they contain, and also the recommendations resulting from the synthesis of evidence. The majority of these recommendations constitute the backbone of the guidelines. The guidelines themselves are much shorter and only contain recommendations and specific information required by physicians to apply these in clinical practice.
Criteria for the comparison of clinical guidelines and their rationales All the observations used for the comparison were collected and analysed by two authors (GG and PM) and checked independently by the other three authors (IC, PD and JM). The structure of the documents was compared by identifying common sections, determining the relative distribution of sections within documents and the groups involved in developing the guidelines. Guidelines content was compared for six common sections that we identified as present in all four guidelines and their rationales: the definition of hypertension and blood pressure stratification, blood pressure measurement methods, cardiovascular risk estimation, lifestyle interventions, general and specific drug therapies and references.
We used a proprietary software called G-DEE 21 (Guidelines Document Engineering Environment) for the automatic recognition of recommendations within the contents of the sections for all four guidelines, avoiding any bias introduced by clinical situations or physicians' interpretation. G-DEE automatically extracts recommendations from plain text documents by recognising deontic operators. Deontic operators are specific linguistic markers characterising recommendations (for example, 'Treatment should start with monotherapy'). 22 We manually compared the recommendations identified by G-DEE in the four guidelines in terms of context application and the corresponding medical practice recommended. Whenever differences were found between guidelines in terms of content, we revisited the rationales further manually to characterise differences in the selection of bibliographic references, the interpretation of published results and the underlying authoring process. We analysed the differences in therapeutic strategy by considering two different clinical situations, namely: (i) patients with hypertension who have been diagnosed but are not yet treated and (ii) hypertensive patients with an initial treatment of antihypertensive drug classes and systolic blood pressure (SBP) X140 mm Hg and/or diastolic blood pressure (DBP) X90 mm Hg. Recommendations from all four guidelines were compared for each of these clinical situations.
Analysis of bibliographical references
We compared the references listed in each rationale using several indicators that were combined for the analysis: the percentage of references common to two or more rationales, the type of reference (meta-analyses, randomized controlled trials, prospective and cross-sectional observational studies), the percentage of self-citations by the working group and the group of reviewers and the ranking of common references with the citation index of Google Scholar, an Internet tool that identifies other documents that have cited articles from among peerreviewed papers, books, abstracts and other scholarly literature from all broad areas of research. We analysed the distribution of the references cited in 1, 2, 3 or 4 rationales as a function of their citation index in Google Scholar by assessing the significance of the overall distribution by one-way analysis of variance (ANOVA).
Results
All four guidelines differed in terms of the patients to whom they applied. The JNC-7 guideline related to all types of patients, whereas the other three guidelines have several exclusion criteria: children and adolescents for ESH/ESC, children and adolescents, pregnant women and women with oral contraception or hormone replacement therapy for HAS, children and adolescents, pregnant women and hypertension associated with other pathologies for NICE. The JNC-7 guideline considered a larger number of conditions compared with the other guidelines, such as obesity and metabolic syndrome, left ventricular hypertrophy, peripheral arterial disease, dementia and more special situations, such as postural hypotension, hypertension in children and adolescents and hypertensive urgencies. The number of experts responsible for the elaboration of guidelines differed widely between the authoring bodies, ranging from 28 for the ESH/ESC (no reading group, such that the external experts reviewing the guideline could be identified), 46 for NICE (21 for authoring, 10 staff and 15 for the reading group) to 75 for HAS (19 for authoring, 10 for the steering committee and 46 for the reading group) and JNC-7 (48 for authoring included 9 from the executive committee and 27 for the reading group). Three rationales mentioned the potential conflicts of interest of each expert, namely relations with industry, government and private health providers for ESH/ESC, financial disclosures for JNC-7 and the participation of private stakeholders for NICE. No mention of conflict of interest or disclosure was included in the HAS guideline, as the working group members have previously declared them through a contract with the agency.
Overall structure of clinical guidelines and their rationales All four guidelines differed substantially in length (not including appendices): 8 pages for ESH/ESC, 20 Figure 1 Distribution of the various sections in the guidelines and rationales. The length of each section is estimated by the number of pages as a proportion of the total number of pages in the guidelines or rationales. The absence of a section on specific drug therapy in the guideline and rationale published by NICE is a consequence of the choice to deal with a targeted population of patients (patients with hypertension not associated with other pathologies).
Comparative study of guidelines G Georg et al for HAS, 21 for JNC-7 and 28 for NICE. Similar length variation was observed for the rationales: 29 pages for ESH/ESC, 98 for HAS, 65 for JNC-7 and 100 for NICE. The ratio between the number of pages in the guidelines and their rationales tended to be similar across guidelines (0.2 for HAS, 0.28 for ESH/ ESC and NICE, and 0.32 for JNC-7). Large differences were also observed in the relative proportion of the guidelines and rationales corresponding to each section ( Figure 1 ). Similar differences in length are associated with the number of references found for each section. Sections on general drug therapy are more developed in the guidelines than in the rationales for HAS and JNC-7, whereas the reverse trend is found for ESH/ESC and NICE guidelines. The selection of evidence in the rationales for reporting in guidelines was associated with large changes in the importance of sections dealing with the definition and measurement of blood pressure (which was more important in the guidelines than in the rationales) and an opposite trend for the lifestyle interventions section. Variations in references also reflect different emphasis for each of the guidelines considered. For instance, the ESH/ESC and HAS guidelines focused mainly on the cardiovascular risk, whereas NICE insisted on the lifestyle interventions and the JNC-7 guideline on the occurrence of associated diseases to hypertension ( Table 1) .
Definition of hypertension and measurement of blood pressure The protocol for measuring blood pressure in the practitioner's office and the definition of hypertension were well described and were similar in all four guidelines. However, some differences were identified, for example, the HAS and NICE guidelines recommended two to three visits, at monthly intervals, for the diagnosis of hypertension, whereas the ESH/ESC and JNC-7 guidelines made no mention of the number or frequency of visits, despite this information being given in their rationales (several office visits for ESH/ESC, and two or more office visits for JNC-7). Only the HAS guideline recommended the use of mean values for the interpretation of multiple blood pressure measurements.
The definition of hypertension, according to the setting of blood pressure measurements, was similar for the ESH/ESC, HAS and JNC-7 guidelines in all circumstances, such as at the office, in ambulatory (day, night and 24-h) and at home. The NICE guideline used the same definition of office hypertension as the other three guidelines, but did not mention the use of measurements in the ambulatory and home settings for the diagnosis of hypertension.
Cardiovascular risk assessment
Identical risk factors were taken into account in ESH/ESC, HAS and JNC-7 guidelines. Most risk factors mentioned in NICE guidelines are similar to that of the others except for a few of them (family history of cardiovascular disease, abdominal obesity, atherosclerosis, stroke, heart disease and peripheral vascular disease). C-reactive protein levels were only mentioned in ESH/ESC guidelines. All four guidelines recommended including cardiovascular risk in the hypertension management. However, differences were also observed in the method used to estimate cardiovascular risk ( Table 2 ). The use of categorical variables to determine risk by JNC-7 and HAS guidelines and of risk scores by NICE and ESH/ESC guidelines produce different results for many patients, which will affect the number of patients being categorised as eligible for treatment.
Lifestyle interventions
Although the lifestyle interventions recommended were generally similar for all four guidelines, some 
Definition of hypertension and measurement of blood pressure
n ¼ 59 (10%) General drug therapy in the absence of other pathologies n ¼ 73 (21%)
n ¼ 156 (28%) Drug therapy in patients with associated diseases n ¼ 87 (26%)
Abbreviations: ESH/ESC, European Society of Hypertension/the European Society of Cardiology; HAS, French National Authority for Health; JNC-7, Joint National Committee; NICE, National Institute for Health and Clinical Excellence. The distribution of references for each section is estimated by the number of references in each section as a proportion of the total number of references in the rationales. The absence of a section on specific drug therapy in the guideline and rationale published by NICE is a consequence of the choice to deal with a targeted population of patients (patients with hypertension not associated with other pathologies).
differences were observed between the NICE guideline and the other guidelines. The NICE guideline did not mention any increase in fruit and vegetable intake, whereas such intake was mentioned in the ESH/ESC, HAS and JNC-7 guidelines. The NICE guideline also recommended the relaxation therapy and the limitation of coffee intake, whereas these interventions were not discussed in the other guidelines.
Drug therapy
All four guidelines recommended common classes of antihypertensive drugs for treatment, such as diuretics, b-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. The ESH/ESC and JNC-7 guidelines also recommended a-blockers, whereas the HAS and NICE guidelines recommended them in case of a fourth drug is required. The guidelines differed in terms of the therapeutic strategy recommended: the ESH/ESC, HAS and NICE guidelines include criteria such as age and/or cardiovascular risk to guide hypertension management. All four guidelines recommended taking into account the cost-effectiveness of the drug treatment (Table 2) . For patients diagnosed with hypertension but not yet treated, only the JNC-7 guideline did not recommend drug therapy, but lifestyle interventions alone, regardless of cardiovascular risk. The other guidelines recommended lifestyle interventions alone or lifestyle interventions associated with drug treatment (monotherapy or bitherapy at low doses) depending on cardiovascular risk. The HAS and ESH/ESC guidelines did not promote a specific class of antihypertensive drug. By contrast, the NICE guideline recommended angiotensin-converting enzyme inhibitors (or b-blockers in case of intolerance) for patients under the age of 55 years and calcium channel blockers or diuretics for patients over 55 years. Comparative study of guidelines G Georg et al
For patients with hypertension uncontrolled despite initial treatment, all four guidelines gave similar recommendations for treatment adaptation: (i) dose optimization, (ii) therapeutic class substitution (in case of intolerance) and (iii) addition of another therapeutic class. As for patients treated for the first time, the HAS and ESH/ESC guidelines did not recommend any specific class, whereas the NICE guideline recommended the complementary classes of those always proposed for patients treated for the first time. The JNC-7 guideline selected thiazide-type diuretics associated with lifestyle interventions, or lifestyle interventions associated with thiazide plus another drug of a different therapeutic class, if SBP X160 mm Hg and/or DBP X100 mm Hg.
Three guidelines (JNC-7, HAS and NICE) clearly described the number of visits required during follow-up. Some differences were also observed on this point. For instance, the JNC-7 guideline recommended visits at monthly intervals until the blood pressure objective is reached and more frequent visits for patients with high cardiovascular risk. The NICE guideline recommended reviewing the patients within 1 year without mentioning the number of visits. The HAS guideline recommended visits every 3 months for patients with high cardiovascular risk and every 6 months for the others. The ESH/ ESC guideline did not contain a follow-up section but mentioned it in their rationale, where visits were proposed every 6 months for patients with low and moderate cardiovascular risk and more frequently for the others.
Concerning the patients with associated diseases, the HAS, JNC-7 and ESH/ESC guidelines contained similar recommendations. The NICE guideline included no specific antihypertensive therapeutic strategies for patients with multiple pathologies. This choice was clearly justified in the rationale, and a mention was made to refer to specific NICE guideline dealing with others pathologies.
Although none of the four guidelines was primarily focused on the prevention of cardiovascular risk, two of them (ESH/ESC and HAS) explicitly mentioned a strategy to reduce other cardiovascular risk factors by recommending the prescription of lipidlowering agents and antiplatelet agents.
Analysis of bibliographic references
The total number of references cited was more for NICE and fairly similar for the other three guidelines: 341 for ESH/ESC, 343 for HAS, 386 for JNC-7 and 564 for NICE. Only 1.2% of the references were common to all four rationales (Figure 2 ), 2.2% were common to three and 8.8% were common to two, the remaining 87.8% of the references were only cited in one rationale. The 47 references common to three or four rationales concerned 31 randomised controlled trials, 12 prospective or cross-sectional observational studies and 4 meta-analyses. The majority (87%) of these references were produced during the last 5 years The association between the number of times a reference was cited across the rationales and the number of citations for these references as reported by Google Scholar was statistically significant (Po0.0001) (Figure 3 ). We found that 37.5% of the references in the ESH/ESC rationale were self-cited by the working group (no reading group could be identified), 8% of references were self-cited for the HAS working group (and 9.6% for the reading group), 22.3% of references were self-cited for the JNC-7 working group (and 10.9% for the reading group) and 2.8% of references were self-cited for the NICE working group (and 0.4% for the reading group).
Grading of the recommendations
The recommendations were not graded in the ESH/ ESC guideline, whereas the HAS and NICE guidelines indicated the level of evidence for each recommendation. The NICE guideline included two gradings, one corresponding to the level of scientific evidence and the other dealing with the strength of the recommendation. The JNC-7 guideline referred each recommendation to its corresponding bibliographic references, and provided a listing in the appendices specifying the type of study and the grade of evidence.
Discussion
The guidelines differed in terms of the presentation of evidence leading to recommendations. Some of the evidence presented in the rationales was not reported in some guidelines, whereas it was in others. This suggests that some differences in content may arise due to differences in the process of evidence analysis, interpretation and synthesis. Examples of this include the frequency of visits for ESH/ESC and JNC-7 (present in rationales and not in guidelines-HAS and NICE guidelines do contain this recommendation) guidelines, the selection of the arm for blood pressure measurements for ESH/ ESC (present in the rationale but not in guidelinesthe other guidelines contain this recommendation), the concept of follow-up normotensive individuals not transferred from the NICE rationale to their guideline and the 'white coat hypertension' for NICE and JNC-7 rationales.
A systematic analysis revealed significant differences between four major guidelines on hypertension management in primary care published within a short time period, although these guidelines had similar structure in terms of the breakdown sections. We identified various stages in the development of guidelines at which their content may start to diverge, accounting for the observed differences: (i) the selection of bibliographic references; (ii) the interpretation of these references; (iii) the structuring of the document; and (iv) the actual formulation of recommendations.
The very low frequency of bibliographic references common to all four rationales (1.2%-the frequency for references common to three rationales was only slightly higher at 2.2%) might lead to the development of different and even contradictory recommendations. However, each section in the guidelines document was based on a specific set of references. The recent update of the ESH/ESC rationale, 20 including a greater number of references (825 instead of 341), did not affect the frequency of the references, which are common to four (1.0%) and three (1.3%) rationales.
The low percentage of common references cannot be accounted for by the existence of literature searching strategies in this domain. The HAS, NICE and JNC-7 guidelines were all developed using standard electronic databases, such as Medline, for their search strategies. Whenever the rationale underlying recommendations was found to differ, differences were also observed in the selection of bibliographic references. Finally, we observed that the practice of hypertension management was mostly based on 47 references, collected between 1990 and 2003, common to three and four rationales. The reason why different conclusions were reached for a given topic, depending on the publications considered and the literature synthesis, has been discussed elsewhere. 23 Expertise in the carrying out of literature reviews and in the collecting and analysis of data were of key importance in the process of guidelines development. 24 It would therefore be useful for the agencies or national medical societies responsible for the development of guidelines to define a common strategy for searching and Comparative study of guidelines G Georg et al reviewing the literature, and for generating a synthesis of the results obtained, but it is not sure that the consistency of the guidelines produced would be improved. Although the common references mainly concern drug treatment, it is in this section that we observed the most important differences in the recommended strategies, such as diuretics for all at one extreme (JNC-7) and age-based drug choice at the other extreme (NICE).
The differences between the references included in these guidelines cannot be accounted for either by publication dates or by self-citation. Anyhow, selfcitation was not related to the predominance of the English-speaking contributions to hypertension research and care, as it is much more marked in European guidelines than in British guidelines. Concerning the publication date, guidelines should be continually updated to take into account advances in medical knowledge and practice. 25 For example, the pharmacological section of the NICE guideline was updated between 2004 and 2006, with the addition of 34 bibliographic references, resulting in a change in the recommended first-line drug treatment in line with the results of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) study. The recent update of ESH/ESC in 2007, with the addition of 484 bibliographic references (including the ASCOT study), did not change the recommended first-line drug treatment. Among all the new references mentioned above for NICE and ESH/ESC, only six were common to both rationales. The structure of working groups 26 (including the number of experts involved) and the consensus process leading to the formulation of recommendations 27, 28 differ significantly between guidelines' producers. Differences in background between group members and the resulting group dynamics during discussions may have affected the formulation of recommendations.
The differences observed between guidelines can be explained not only by the differences in process but also by the context in which these guidelines were produced, as two types of guidelines can be distinguished, namely those from public agencies (NICE and HAS) and those from medical societies (ESH/ESC and JNC-7).
A universal guideline seems an impossible goal to achieve, as guidelines should precisely take into account local medical practices and specific organization of care in each country. However, an achievable objective in that direction would be to minimize the bias in the selection of bibliographic references by implementing systematic reviews, as proposed by the G-I-N community. 29 Several recent international initiatives, such as GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) 30 and the ADAPTE group, 31 should help to harmonize guidelines in the near future.
A more exhaustive choice of bibliographic references and a consistency check should become the first step to improve coherence between guidelines.
